In November 2021, the White House paid drugmaker Pfizer $5.3 billion for 10 million treatment courses of its experimental COVID-19 treatment.
Initial study findings showed that Paxlovid cut the risk of hospitalization and death by nearly 90% in people with mild to moderate coronavirus infections.
The drugmaker limited its study to people who were unvaccinated and who faced the greatest risk from the virus due to age or health problems, such as obesity.
Pfizer will cease enrollment into the EPIC-SR trial due to low rate of hospitalization or death in the standard-risk population.
Pfizer already has $5.3 billion in hand from taxpayers, and has locked in "blockbuster status" (defined as one billion dollars in sales of a single drug).
In January, the U.S. announced a confidential additional "commitment" to order an additional 10 million doses (at the price of 5.6 billion) giving Pfizer highly sought after "super blockbuster status."
Secret FDA Meetings Sound Familiar
In order to amend the protocol following FDA submission, Pfizer would have had to communicate about it with the FDA formally and in writing.
A former Pfizer non-scientist executive, Patrizia Cavazzoni, now the head of the FDA's Center for Drug Evaluation and Research, would have to approve the change.
Pfizer CEO Albert Bourla announced plans to spend over $100 million to increase Paxlovid production and commit hundreds of new employees as its way to maintain appearances with the White House and Pfizer investors.
Americans Never Needed Paxlovid; Omicron/Delta COVID-19 Symptoms Are Mild
https://thebluestateconservative.com/2022/06/27/more-covid-waste-biden-white-house-paying-10-6-billion-for-pfizers-covid-19-paxlovid-flop/
No comments:
Post a Comment